Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 1.84
Ask: 1.96
Change: -0.14 (-6.86%)
Spread: 0.12 (6.522%)
Open: 2.00
High: 2.01
Low: 2.00
Prev. Close: 2.04
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Report & Notice of AGM

7 Jun 2017 07:00

RNS Number : 3430H
Immupharma PLC
07 June 2017
 

 

 7 June 2017

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

 

ANNUAL REPORT AND ACCOUNTS POSTED TO SHAREHOLDERS

NOTICE OF ANNUAL GENERAL MEETING ON 30 JUNE 2017 @ 10.30 AM

 

INVESTOR PRESENTATION TO FOLLOW AT 11.30 AM

 

VENUE: SKY LIGHT CITY, 50 BASINGHALL STREET, LONDON, EC2

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that today the Annual Report and Accounts for the year ended 31 December 2016 has today been posted to shareholders.

This report includes the 'Annual Report of the Annual General Meeting' ('AGM') as well as the 'Notice of the 2017 AGM', which will be available later today, in electronic form, for download on the Company's website www.immupharma.org.

ImmuPharma's AGM will be held on Friday 30 June at 10:30am at Sky Light City Tower, 50 Basinghall Street, EC2V 5DE.

Investor Meeting @ 11.30am on 30 June 2017

 

ImmuPharma has confirmed that it will be hosting an Investor Presentation and luncheon immediately following the Company's Annual General Meeting at 11.30am. Please contact Lisa Baderoon at lisa.baderoon@immupharma.com if you would like to attend this event.

 

-Ends-

 

 

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

 

Northland Capital Partners Limited (Joint Broker)

Patrick Claridge, David Hignell, Corporate Finance

Rob Rees, Corporate Broking

 

 

+44 (0)20 3861 6625

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOASSAFMMFWSELM
Date   Source Headline
4th Jun 20197:00 amRNSNotice of AGM and posting of Report & Accounts
24th May 20197:00 amRNSFINAL RESULTS
7th May 20197:00 amRNSCorporate Update
1st Apr 20197:00 amRNSUpdate on Nucant Cancer Programme
14th Mar 20197:00 amRNSCorporate Update
26th Feb 20197:00 amRNSTechnology review published-Nature Communications
31st Dec 20187:00 amRNSClinical Development Collaboration with Incanthera
21st Dec 20184:41 pmRNSSecond Price Monitoring Extn
21st Dec 20184:36 pmRNSPrice Monitoring Extension
20th Dec 20184:35 pmRNSPrice Monitoring Extension
17th Dec 20187:00 amRNSAppointment of Nominated Adviser
7th Dec 20187:00 amRNSUpdate on Corporate Activities
29th Nov 20184:40 pmRNSSecond Price Monitoring Extn
29th Nov 20184:35 pmRNSPrice Monitoring Extension
28th Nov 20184:40 pmRNSSecond Price Monitoring Extn
28th Nov 20184:35 pmRNSPrice Monitoring Extension
23rd Nov 20184:40 pmRNSSecond Price Monitoring Extn
23rd Nov 20184:35 pmRNSPrice Monitoring Extension
21st Nov 20184:40 pmRNSSecond Price Monitoring Extn
21st Nov 20184:35 pmRNSPrice Monitoring Extension
7th Nov 20184:35 pmRNSPrice Monitoring Extension
1st Nov 20181:38 pmRNSNominated Adviser Status
26th Sep 20187:00 amRNSInterim Results
19th Sep 20187:00 amRNSAppointment of Joint Brokers
7th Sep 20187:00 amRNSCorporate Update
10th Jul 20184:40 pmRNSSecond Price Monitoring Extn
10th Jul 20184:35 pmRNSPrice Monitoring Extension
28th Jun 201812:16 pmRNSResult of AGM
14th Jun 20187:00 amRNSResults of CIDP Pre-Clinical Data
6th Jun 20187:00 amRNSNotice of AGM & Posting of Annual Report
29th May 20187:00 amRNSUpdate on Pivotal Phase III Trial of Lupuzor
29th May 20187:00 amRNSFinal Results
24th Apr 201811:59 amRNSHolding(s) in Company
20th Apr 20188:24 amRNSHolding(s) in Company
19th Apr 20188:05 amRNSHolding(s) in Company
17th Apr 20187:00 amRNSTopline results of Lupuzor Pivotal Phase III Trial
28th Mar 20187:00 amRNSAppointment of Joint Broker
23rd Mar 20187:00 amRNSLupuzor Pivotal Phase III Study Update
5th Mar 20184:13 pmRNSAIM Notice (17)
15th Feb 20187:00 amRNSLondon Investor Evening
9th Feb 20182:00 pmRNSHolding(s) in Company
7th Feb 20189:35 amRNSHolding(s) in Company
5th Feb 20187:00 amRNSHolding(s) in Company
31st Jan 201810:23 amRNSHolding(s) in Company
24th Jan 20187:00 amRNSSuccessful Placing to Raise £10 Million
18th Jan 20187:00 amRNSCompletion of LupuzorT Pivotal Phase III Study
21st Dec 20177:05 amRNSGrant of Options
21st Dec 20177:00 amRNSLast patient completes dosing in LupuzorT Trial
28th Nov 201712:00 pmRNSHolding(s) in Company
24th Nov 20171:32 pmRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.